Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia

Schizophrenia Research

Volumn 105, Issue 1-3, 2008, Pages 201-207

  Batki, Steven L ^a,b   Leontieva, Luba ^b   Dimmock, Jacqueline A ^b   Ploutz Snyder, Robert ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Alcohol; Craving; Naltrexone; Negative symptom; PANSS; Positive symptom; Schizophrenia

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; CANNABIS; COCAINE; NALTREXONE; NEUROLEPTIC AGENT; PLACEBO;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; BLUNTED AFFECT; CANNABIS ADDICTION; CLINICAL TRIAL; COCAINE DEPENDENCE; DISEASE ASSOCIATION; EUPHORIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; THINKING IMPAIRMENT; WITHDRAWAL SYNDROME;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; BEHAVIOR, ADDICTIVE; COCAINE-RELATED DISORDERS; COGNITION DISORDERS; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EUPHORIA; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; NALTREXONE; NARCOTIC ANTAGONISTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 52949092291     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.06.020     Document Type: Article

References (22)

1. Addington D., Addington J., and Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry 22 (1993) 39-44 (suppl)
2. Anton R.F., Moak D.H., and Latham P.K. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch. Gen. Psychiatry 53 (1996) 225-231
3. Batki S.L., Dimmock J.A., Hameed A., Cornell M., Wade M., Albrecht J., Maisto S.A., and Carey K.B. Alcohol use measures in naltrexone treatment of alcohol dependence in schizophrenia: preliminary analysis. Alcohol., Clin. Exp. Res. 25 5:suppl. (2001) 93A
4. (abstract). Batki S.L., Dimmock J.A., Ploutz-Snyder R., Carey K.B., Maisto S.A., Cavallerano M., Gallinger L., and Leontieva L. Naltrexone treatment for patients with schizophrenia and alcohol dependence: the role of adherence-preliminary findings. Alcohol., Clin. Exp. Res. 31 6: suppl. (2007) 255A (abstract S028)
5. Chambers R.A., Krystal J.H., and Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 50 (2001) 71-83
6. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 35 (1999) S93-S100 Suppl
7. D'Souza D.C., Gil R.B., Madonick S., Perry E.B., Forselius-Bielen K., Braley G., Donahue L., Tellioglu T., Zimolo Z., Gueorguieva R., and Krystal J. Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia. Neuropsychopharmacology 31 (2006) 2767-2775
8. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). Biometrics Research (2002), New York State Psychiatric Institute, New York
9. Green A.I., Zimmet S.V., Strous R.D., and Schildkraut J.J. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harv. Rev. Psychiatry 6 (1999) 287-296
10. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
11. Kay S.R., Opler L.A., and Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Technical Manual (2006), MHS, North Tonawanda, New York
12. Khantzian E.J. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv. Rev. Psychiatry 4 (1997) 231-244
13. Luborsky L. Clinician's judgments of mental health. Arch. Gen. Psychiatry 7 (1962) 407-417
14. Margolese H.C., Negrete J.C., Tempier R., and Gill K. A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: changes in psychiatric symptoms and substance use. Schizophr. Res. 83 (2006) 65-75
15. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., and Argeriou M. The Fifth Edition of the Addiction Severity Index. J. Subst. Abuse Treat. 9 (1992) 199-213
16. Mueser K.T., Drake R.E., and Wallach M.A. Dual diagnosis: a review of etiological theories. Addict. Behav. 23 (1998) 717-734
17. Nisell M., Nomikos G.G., and Svensson T.H. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol. Toxicol. 76 (1995) 157-162
18. Potvin S., Sepehry A.A., and Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol. Med. 35 (2005) 1-10
19. Roth R.M., Brunette M.F., and Green A.I. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?. Curr. Psychiatry Rep. 7 (2005) 283-291
20. Sobell L.C., and Sobell S.M. Timeline Follow-Back (1992), The Humana Press, Inc., Totowa, New Jersey
21. Talamo A., Centorrino F., Tondo L., Dimitri A., Hennen J., and Baldessarini R.J. Comorbid substance-use in schizophrenia: relation to positive and negative symptoms. Schizophr. Res. 86 (2006) 251-255
22. Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am. J. Addict. 15 (2006) 345-355